Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adlai Nortye

www.adlainortye.com

Latest From Adlai Nortye

Deal Watch: Pfizer Offloads Troubled ADHD Products To Manufacturer Tris

Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.

Deals Business Strategies

Novartis' SOLAR-1 Study Shines on Alpelisib In Breast Cancer

The selective PI3K inhibitor, alpelisib, met its primary PFS endpoint in top-line data from the SOLAR-1 study, but further details are needed from the trial in order to judge the drug's likely penetration of the HR-positive, HER2-negative breast cancer population.

 

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Adlai Nortye
  • Senior Management
  • Carsten Lu, CEO
    Ruirong Yuan, MD, Pres. & CMO
    Wenle Xia, MD, CSO
    Jason Lu, MD, PhD, CBO
  • Contact Info
  • Adlai Nortye
    Phone: 571 28918366
    21st Fl., Bldg. 2, No. 452, 6th St.
    Hangzhou, 310018
    China
UsernamePublicRestriction

Register